Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M275392-5mg | 5mg | In stock | $127.90 | |
M275392-10mg | 10mg | In stock | $206.90 | |
M275392-25mg | 25mg | In stock | $434.90 | |
M275392-50mg | 50mg | In stock | $711.90 | |
M275392-100mg | 100mg | In stock | $1,137.90 |
Allosteric, selective, non-ATP competitive\xa0pan-Akt inhibitor
Synonyms | miransertib|1313881-70-7|ARQ-092|AKT inhibitor 2|ARQ 092 Free Base|ARQ092|ARQ 092|Miransertib [INN]|Miransertib [USAN]|Miransertib [WHO-DD]|T1DQI1B52Y|3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine|3-(3-(4-(1-aminocy |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Allosteric, selective, non-ATP competitive\xa0pan-Akt inhibitor (IC 50 = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively). Selective for Akt isoforms over a panel of 303 other kinases. |
Storage Temp | Protected from light,Store at -20°C,Desiccated |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ALLOSTERIC MODULATOR, INHIBITOR |
Mechanism of action | Allosteric modulator of AKT serine/threonine kinase 1;Inhibitor of AKT serine/threonine kinase 1;Allosteric modulator of AKT serine/threonine kinase 2;Inhibitor of AKT serine/threonine kinase 2;Allosteric modulator of AKT serine/threonine kinase 3;Inhibit |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Shipped at 4°C. Store at -20°C. Store In the Dark. Store under desiccating conditions. |
ALogP | 3.8 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488201568 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488201568 |
IUPAC Name | 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine |
INCHI | InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30) |
InChi Key | HNFMVVHMKGFCMB-UHFFFAOYSA-N |
Canonical SMILES | C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N |
Isomeric SMILES | C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N |
Alternate CAS | 1313881-70-7 |
PubChem CID | 53262401 |
MeSH Entry Terms | 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo(4,5-b)pyridin-2-yl)pyridin-2-amine;ARQ 092;Miransertib |
Molecular Weight | 432.53 |
PubChem SID | 488201568 |
---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
D2306314 | Certificate of Analysis | Feb 01, 2024 | M275392 |
D2306541 | Certificate of Analysis | Jan 15, 2024 | M275392 |
D2306536 | Certificate of Analysis | Jan 15, 2024 | M275392 |
D2306470 | Certificate of Analysis | Jan 15, 2024 | M275392 |
D2306468 | Certificate of Analysis | Jan 15, 2024 | M275392 |
D2306313 | Certificate of Analysis | Jan 12, 2024 | M275392 |
D2306370 | Certificate of Analysis | Jan 12, 2024 | M275392 |
D2306422 | Certificate of Analysis | Jan 12, 2024 | M275392 |
D2306469 | Certificate of Analysis | Jan 12, 2024 | M275392 |
D2306542 | Certificate of Analysis | Jan 12, 2024 | M275392 |
Solubility | Soluble ine DMSO to 159.92 mM and in ethanol to 8.52 mM |
---|
Pictogram(s) | GHS08 |
---|---|
Signal | Warning |
Hazard Statements | H373:Causes damage to organs through prolonged or repeated exposure |
Precautionary Statements | P501:Dispose of contents/container to ... P260:Do not breathe dust/fume/gas/mist/vapors/spray. P319:Get medical help if you feel unwell. |
1. Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S et al.. (2016) Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.. J Med Chem, 59 (13): (6455-69). [PMID:27305487] |
2. Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B. (2015) Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.. PLoS ONE, 10 (10): (e0140479). [PMID:26469692] |
3. Lindhurst MJ, Yourick MR, Yu Y, Savage RE, Ferrari D, Biesecker LG. (2015) Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.. Sci Rep, 5 (3): (17162). [PMID:26657992] |
4. Jiang Y et al.. (2022) Transcriptomic and ChIP-seq Integrative Analysis Identifies KDM5A-Target Genes in Cardiac Fibroblasts.. Front Cardiovasc Med, 9 (929030). [PMID:35845066] |